SHPG

Shire Shs Sponsored American Deposit Receipt Repr 3 Shs

Healthcare


Presented:10/30/2017
Price:$145.76
Cap:$44.35B
Current Price:$160.79
Cap:$49.20B

Presented

Date10/30/2017
Price$145.76
Market Cap$44.35B
Ent Value$74.39B
P/E Ratio67.75x
Book Value$103.37
Div Yield0.21%
Shares O/S304.23M
Ave Daily Vol1,182,134
Short IntN/A

Current

Price$160.79
Market Cap$49.20B
Shire Plc is a biopharmaceutical company. The company focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. The company's products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr and foznol. Shire was founded in 1986 and is headquartered in Dublin, Ireland.

Publicly traded companies mentioned herein: Amicus Therapeutics Inc (FOLD), BioCryst Pharmaceuticals Inc (BCRX), Bioverativ Inc (BIVV), CSL Ltd (CSL AU), Shire PLC (SHPG), Roche Holding AG (RHHBY), Zydus

Highlights

The presenter is short Shire PLC (SHPG) at $145 and sees further downside risk for shareholders based on numerous competitive threats that are presently impacting many of its larger franchises. To name a few, generic Lialda and CSL’s Haegarda are taking share from Shire’s therapies (for ulcerative colitis and HAE, respectively), and concerns about Roche’s emicizumab (ACE910) remain an overhang on the stock. While SHPG stock is widely owned, and being short has been “painful” at times due to sharp spikes, it is difficult for him to envision the pressure on key contributors to the business abating near-term.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.